Cargando…

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC

OBJECTIVES: This study aimed to evaluate the correlation between positive PD-L1 expression and driver gene mutations in NSCLC and to seek preliminary evidence in favor of the strategy of PD-L1 inhibitors plus targeted agents. RESULTS: The overall analyses revealed that positive PD-L1 expression had...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Haitao, Chen, Huijuan, Luo, Shuimei, Li, Lina, Zhou, Sijing, Shen, Ruifen, Lin, Heng, Xie, Xianhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410323/ https://www.ncbi.nlm.nih.gov/pubmed/28423587 http://dx.doi.org/10.18632/oncotarget.15627

Ejemplares similares

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer
por: Lin, Heng, et al.
Publicado: (2016)

Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials
por: Xie, Xianhe, et al.
Publicado: (2017)

Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer
por: Lin, Heng, et al.
Publicado: (2017)

Evaluation on Efficacy and Safety of Arsenic Trioxide Plus Transcatheter Arterial Chemoembolization Versus Transcatheter Arterial Chemoembolization alone for Unresectable Primary Liver Cancer
por: Yang, Haitao, et al.
Publicado: (2017)

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases
por: Luo, Shuimei, et al.
Publicado: (2015)

Predictive value of positron emission tomography for the prognosis of molecularly targeted therapy in solid tumors
por: Xie, Xianhe, et al.
Publicado: (2018)

A Comprehensive Model for Predicting Recurrence and Survival in Cases of Chinese Postoperative Invasive Breast Cancer
por: Xie, Xianhe, et al.
Publicado: (2017)

The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants
por: Wu, Qing, et al.
Publicado: (2022)

Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors
por: Wan, Luying, et al.
Publicado: (2022)

Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC
por: Ancel, Julien, et al.
Publicado: (2019)

Upregulation of KHDC1L promotes the proliferation and inhibits apoptosis in head and neck squamous cell carcinoma
por: Zhang, Qi, et al.
Publicado: (2023)

Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer
por: Wang, Lili, et al.
Publicado: (2022)

Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients
por: Wan, Luying, et al.
Publicado: (2022)

The Reproducibility of Histopathologic Assessments of Programmed Cell Death-Ligand 1 Using Companion Diagnostics in NSCLC
por: Yuan, Pei, et al.
Publicado: (2020)

Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype
por: Pandey, Rahul Kumar, et al.
Publicado: (2022)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
por: Wang, Huijuan, et al.
Publicado: (2019)

Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
por: LIAM, Chong Kin, et al.
Publicado: (2023)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC
por: Negrao, Marcelo V., et al.
Publicado: (2022)

Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
por: Liang, Wenhua, et al.
Publicado: (2019)

Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
por: Vecchiarelli, Silvia, et al.
Publicado: (2018)

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors
por: Bains, Savreet, et al.
Publicado: (2022)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
por: Liao, Haotian, et al.
Publicado: (2019)

The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis
por: Zhang, Jingyi, et al.
Publicado: (2021)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma
por: Sheng, Qiu-Ju, et al.
Publicado: (2020)

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
por: Zhou, Tingting, et al.
Publicado: (2018)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants
por: Xie, Xianhe, et al.
Publicado: (2020)

Roles of programmed death protein 1/programmed death-ligand 1 in secondary brain injury after intracerebral hemorrhage in rats: selective modulation of microglia polarization to anti-inflammatory phenotype
por: Wu, Jie, et al.
Publicado: (2017)

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
por: Zeng, Jing, et al.
Publicado: (2016)

Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
por: Kim, Ji Hye, et al.
Publicado: (2020)

Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis
por: Kim, Jinchul, et al.
Publicado: (2018)

Correlation of PIK3CA mutation with programmed death ligand-1 (PD-L1) expression and their clinicopathological significance in colorectal cancer
por: Ahn, Ae Ri, et al.
Publicado: (2021)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
por: Luo, Fan, et al.
Publicado: (2021)

Implementation of programmed death-ligand 1 (PD-L1) expression as a prognostic biomarker for patients with lung cancer
por: Li, Huijuan, et al.
Publicado: (2022)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ka969che8gjrc0kjmpn2r6j03v